Bhubaneswar: The human clinical trial of India’s first indigenous anti-COVID vaccine ‘Covaxin’ commenced at Institute of Medical Sciences and SUM Hospital (IMS & SUM) here today.
The trial is being carried out at special laboratory — Preventive and Therapeutic Clinical Trial Unit (PTCTU) of the hospital in accordance with the protocols laid down by the Drugs Controller General of India (DCGI).
This is the second part of the Phase I human trials for the vaccine with a volunteer being administered the vaccine candidate today at the IMS SUM hospital today.
The vaccine was administered to several persons who had volunteered to be part of the trial, Principal Investigator of the trial process Dr. E.Venkat Rao said.
The vaccination here was done after the volunteers had undergone a rigorous screening procedure.
There was a lot of enthusiasm among people who offered to volunteer for the trial. Those who were administered the vaccine have been kept under observation and they were absolutely fine, Rao said.
The IMS & SUM is one of the twelve centers in the country selected where the phase one and two human trials will be carried out for the made in India vaccine for Coronavirus, developed by India against COVID-19 and is derived from a strain of SARS- CoV-2 isolated by ICMR-National Institute of Virology, Pune.
ICMR and Bharat Biotech are jointly working for the preclinical as well as clinical development of this vaccine.
Comments are closed.